The small molecule KZR616, which inhibits both PSMB8 and 10 (134), is the only selective ImP inhibitor to currently be tested clinically, although not for a cancer indication, but as a treatment for autoimmunity (NCT04628936, NCT04039477, NCT03393013, NCT04033926, NCT05569759, NCT05781750). The gene discussed is PSMB8; the disease is cancer.